Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1526 ARTÍCULOS , VIENDO DEL 16 AL 30

Inhibitors of Cholinesterases in Pharmacology: the Current Trends

Pohanka M.

Mini Rev Med Chem. 2020;20(15):1532-1542. doi: 10.2174/1389557519666191018170908.

An Increasing Role of Polyphenols as Novel Therapeutics for Alzheimer's: A Review

Karim N, Khan H, Khan I, Guo O, Sobarzo-Sánchez E, Rastrelli L, Kamal MA.

Med Chem. 2020;16(8):1007-1021. doi: 10.2174/1573406415666191105154407.

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

Tolar M, Abushakra S, Sabbagh M.

Alzheimers Dement. 2020 Nov;16(11):1553-1560. doi: 10.1016/j.jalz.2019.09.075. Epub 2020 Jan 3.

Lipid lowering and Alzheimer disease risk: A mendelian randomization study

Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD.

Ann Neurol. 2020 Jan;87(1):30-39. doi: 10.1002/ana.25642.

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial

Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R; Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group.

JAMA Neurol. 2020 Feb 1;77(2):164-174. doi: 10.1001/jamaneurol.2019.3762.

Pragmatic Trials and Repurposed Drugs for Alzheimer Disease

Schneider LS.

JAMA Neurol. 2020 Feb 1;77(2):162-163. doi: 10.1001/jamaneurol.2019.3784.

Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer's Disease

Seo DO, Holtzman DM.

J Gerontol A Biol Sci Med Sci. 2020 Jun 18;75(7):1232-1241. doi: 10.1093/gerona/glz262.

Hormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature

Yare K, Woodward M.

J Alzheimers Dis. 2020;73(1):23-37. doi: 10.3233/JAD-190896.

Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems

Altinoglu G, Adali T.

Curr Drug Targets. 2020;21(7):628-646. doi: 10.2174/1389450120666191118123151.

A disease-modifying treatment for Alzheimer's disease: focus on the trans-sulfuration pathway

Berry T, Abohamza E, Moustafa AA.

Rev Neurosci. 2020 Apr 28;31(3):319-334. doi: 10.1515/revneuro-2019-0076.

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR.

JAMA Neurol. 2020 Feb 1;77(2):199-209. doi: 10.1001/jamaneurol.2019.3988.

Nanotechnology to improve the Alzheimer's disease therapy with natural compounds

Ramalho MJ, Andrade S, Loureiro JA, do Carmo Pereira M.

Drug Deliv Transl Res. 2020 Apr;10(2):380-402. doi: 10.1007/s13346-019-00694-3.

Alzheimer's Disease: A Contextual Link with Nitric Oxide Synthase

Dubey H, Gulati K, Ray A.

Curr Mol Med. 2020;20(7):505-515. doi: 10.2174/1566524019666191129103117.

Progress in Target Drug Molecules for Alzheimer's Disease

Xie J, Liang R, Wang Y, Huang J, Cao X, Niu B.

Curr Top Med Chem. 2020;20(1):4-36. doi: 10.2174/1568026619666191203113745.

Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention

Lim JW, Lee J, Pae AN.

BMB Rep. 2020 Jan;53(1):47-55. doi: 10.5483/BMBRep.2020.53.1.279.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias